Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia

Disease-specific assessments are not currently available for patients with Parkinson’s disease dementia (PDD). This study evaluated the criterion-related validity and test—retest reliability of the Alzheimer’s Disease Assessment scale cognitive subscale (ADAS-cog) in terms of sensitivity for differentiation between mild and moderate severity impairment in PDD. Six other dementia rating scales and cognitive tests were also examined. A total of 113 patients with PDD or Alzheimer disease were recruited into this 4-week, multicenter study, segregated into 2 severity groups based on Mini-Mental State Examination (MMSE) score. Mean ADAS-cog scores showed a statistically significant separation between mild and moderate severity patients in both dementias (P < .001). For the ADAS-cog, test—retest Spearman correlation coefficients were significant for each dementia type and severity. This study demonstrated the criterion-related validity and test—retest reliability for ADAS-cog in patients with PDD and strong correlations with MMSE. This supports the validity of previous results obtained with these measures in studies of patients with PDD.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  J. Cummings,et al.  A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson’s Disease versus Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[3]  K. Wesnes.  Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System , 2008, Neurodegenerative Diseases.

[4]  A. Lang,et al.  A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  P. Riederer,et al.  Cognitive impairment in 873 patients with idiopathic Parkinson's disease , 2008, Journal of Neurology.

[6]  K. Langa,et al.  Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study , 2007, Neuroepidemiology.

[7]  R. Bullock,et al.  Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. , 2007, Current Alzheimer research.

[8]  D. Aarsland,et al.  Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  D. Salmon,et al.  Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[11]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[12]  D. Press.  Parkinson's disease dementia--a first step? , 2004, The New England journal of medicine.

[13]  N. Bohnen,et al.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.

[14]  M. Emre.  Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.

[15]  P. Manos.  Ten‐point clock test sensitivity for Alzheimer's Disease in patients with MMSE scores greater than 23 , 1999, International journal of geriatric psychiatry.

[16]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[17]  L. Hartlage.  The Halstead-Reitan neuropsychology test battery: Theory and clinical interpretation second edition: By Ralph M. Reitan, PhD & Deborah Wolfson, PhD, Tucson, Az: Neuropsychology Press, 1993. , 1994 .

[18]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[19]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[20]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[21]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[22]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[23]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[24]  Murat Emre,et al.  Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. , 2007, Journal of Alzheimer's disease : JAD.

[25]  S. Ferris.  Clinical Trials in AD: Are Current Formats and Outcome Measures Adequate? , 2002, Alzheimer disease and associated disorders.

[26]  H. Braak,et al.  Evolution of neuronal changes in the course of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[27]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.